Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (421-430 of 713) with videos related to

Pageof 72
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2016
Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal DysfunctionKoji Sasaki, Amit Lahoti, Elias Jabbour, et al.
Blood|July 13, 2013
Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)Wael Saber, Corey S Cutler, Ryotaro Nakamura, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2013
Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemiaAlireza Eghtedar, Hagop Kantarjian, Elias Jabbour, et al.
American Journal of Hematology|November 2, 2012
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemiaNaval Daver, Paolo Strati, Elias Jabbour, et al.
Blood|March 15, 2003
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alphaJorge Cortes, Francis Giles, Susan O'Brien, et al.
Leukemia & Lymphoma|April 21, 2011
Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?Lisa M Lima, Keeran Sampat, Sarit Assouline, et al.
Cancer|June 22, 2010
Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice dailyGiuseppe Saglio, Andreas Hochhaus, Yeow Tee Goh, et al.
Blood|September 6, 2007
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitorsJorge Cortes, Elias Jabbour, Hagop Kantarjian, et al.
Blood|November 26, 2008
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical responseKeith W Pratz, Jorge Cortes, Gail J Roboz, et al.
Haematologica|February 16, 2015
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaNaval Daver, Deborah Thomas, Farhad Ravandi, et al.
Pageof 72

Showing results (421-430 of 713) with videos related to

Sort By:
Pageof 72
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2016
Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal DysfunctionKoji Sasaki, Amit Lahoti, Elias Jabbour, et al.
Blood|July 13, 2013
Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)Wael Saber, Corey S Cutler, Ryotaro Nakamura, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2013
Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemiaAlireza Eghtedar, Hagop Kantarjian, Elias Jabbour, et al.
American Journal of Hematology|November 2, 2012
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemiaNaval Daver, Paolo Strati, Elias Jabbour, et al.
Blood|March 15, 2003
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alphaJorge Cortes, Francis Giles, Susan O'Brien, et al.
Leukemia & Lymphoma|April 21, 2011
Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?Lisa M Lima, Keeran Sampat, Sarit Assouline, et al.
Cancer|June 22, 2010
Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice dailyGiuseppe Saglio, Andreas Hochhaus, Yeow Tee Goh, et al.
Blood|September 6, 2007
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitorsJorge Cortes, Elias Jabbour, Hagop Kantarjian, et al.
Blood|November 26, 2008
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical responseKeith W Pratz, Jorge Cortes, Gail J Roboz, et al.
Haematologica|February 16, 2015
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaNaval Daver, Deborah Thomas, Farhad Ravandi, et al.
Pageof 72